Cancer chemoprevention through dietary avonoids: what's limiting?

作     者：Haneen Amawi Charles R. Ashby Jr Amit K. Tiwari 

作者机构：Department of Pharmacology and Systems Therapeutics College of Pharmacy and Pharmaceutical Sciences University of Toledo Toledo OH 43560USA Pharmaceutical Sciences College of Pharmacy St. John’s UniversityQueens NY 11432 USA Department of Pharmacology and Experimental Therapeutics College of Pharmacy and Pharmaceutical Sciences University of Toledo Toledo OH 43614 USA 

出 版 物：《Chinese Journal of Cancer》 (Chinese Journal of Cancer)

年 卷 期：2017年第36卷第10期

页      面：455-467页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by seed-fund to AKT from Department of Pharmacology and Experimental Therapeutics at UT 

主　　题：Flavonoids Chemoprevention Silybin Silymarin Natural product drug development Pharmacokinetic challenges 

摘      要：Flavonoids are polyphenols that are found in numerous edible plant species. Data obtained from preclinical and clinical studies suggest that specific flavonoids are chemo-preventive and cytotoxic against various cancers via a multitude of mechanisms. However, the clinical use of flavonoids is limited due to challenges associated with their e ective use, including(1) the isolation and purification of flavonoids from their natural resources;(2) demonstration of the e ects of flavonoids in reducing the risk of certain cancer, in tandem with the cost and time needed for epidemiological studies, and(3) numerous pharmacokinetic challenges(e.g., bioavailability, drug–drug interactions, and metabolic instability). Currently, numerous approaches are being used to surmount some of these challenges, thereby increasing the likelihood of flavonoids being used as chemo-preventive drugs in the clinic. In this review, we summarize the most important challenges and e orts that are being made to surmount these challenges.